Leap Therapeutics price target lowered to $20 from $30 at Baird

Baird analyst Joel Beatty lowered the firm’s price target on Leap Therapeutics to $20 from $30 and keeps an Outperform rating on the shares. The firm said they are positive on the update that all of the responses in CRC with DKN-01 announced last month have now been confirmed. This provides reassurance, around the 130-patient randomized controlled part B of the study that has now initiated.